Developing country pharmaceutical industry

in page functions

More than half of Gavi vaccine suppliers are based in emerging markets. The increased competition is driving down the price of vaccines

Bandung442 Edy Purnomo

DCVN logoGavi aims to make vaccines more affordable for low-income countries by expanding the range of suppliers to include developing country manufacturers. As such, the Vaccine Alliance has assigned a seat on its Board to a representative of the Developing Countries Vaccine Manufacturing Network (DCVMN), a voluntary alliance of 27 state-owned and private companies from 14 countries.

DCVMN goals

DCVMN's goals are closely aligned to those of Gavi and include:

  • providing a consistent, sustainable supply of quality vaccines and related technologies at affordable prices, particularly those needed by developing countries;
  • gaining recognition of the role developing country vaccine producers play in assuring availability of vaccines;
  • expanding the role of its members within Gavi;
  • encouraging the research and development efforts of its full members.

Role on the Gavi Board

The Vaccine Alliance assigns a seat on its Board to a developing country pharmaceutical industry, currently held by the Serum Institute of India, a member of the Developing Countries Vaccine Manufacturing Network (DCVMN), a voluntary alliance of state-owned and private companies. Developing country manufacturers are also represented on the Board's Executive Committee.

DCVMN also seeks to assist members to achieve WHO prequalification and to foster collaboration and communication in the international vaccine industry.

All full members of the DCVMN, who are located in countries with fully functioning regulatory authorities, are prequalified by WHO to supply vaccines both to domestic and international markets, including UNICEF, WHO and Gavi.

Decline in prices

There are already signs that increased competition from developing country pharmaceutical industry is driving down the price of Gavi-supported vaccines. More than half of Gavi vaccine suppliers are now based in emerging markets, with a consequent decline in prices, including for tetravalent and pentavalent vaccines.

Investment and technology transfer from industrialised country pharmaceutical industries is also broadening the range of vaccines produced in developing countries.

+215 million

By the end of 2014, 15 countries in the African meningitis belt had collectively immunised more than 215 million people against meningitis A with support from Gavi.

WHO 2014

More facts...

close icon

modal window here